These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 29641993)

  • 1. Pre-clinical validation of a next generation sequencing testing panel.
    Lüsebrink J; Pieper M; Tillmann RL; Brockmann M; Schildgen O; Schildgen V
    Exp Mol Pathol; 2018 Jun; 104(3):170-174. PubMed ID: 29641993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of amplicon-based next generation DNA sequencing for diagnostic gene mutation profiling in oncopathology.
    Sie D; Snijders PJ; Meijer GA; Doeleman MW; van Moorsel MI; van Essen HF; Eijk PP; Grünberg K; van Grieken NC; Thunnissen E; Verheul HM; Smit EF; Ylstra B; Heideman DA
    Cell Oncol (Dordr); 2014 Oct; 37(5):353-61. PubMed ID: 25209392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of the QIAGEN GeneReader NGS system for detection of KRAS mutations, validated by the QIAGEN Therascreen PCR kit and alternative NGS platform.
    Darwanto A; Hein AM; Strauss S; Kong Y; Sheridan A; Richards D; Lader E; Ngowe M; Pelletier T; Adams D; Ricker A; Patel N; Kühne A; Hughes S; Shiffman D; Zimmermann D; Te Kaat K; Rothmann T
    BMC Cancer; 2017 May; 17(1):358. PubMed ID: 28532404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Towards a Next-Generation Sequencing Diagnostic Service for Tumour Genotyping: A Comparison of Panels and Platforms.
    Burghel GJ; Hurst CD; Watson CM; Chambers PA; Dickinson H; Roberts P; Knowles MA
    Biomed Res Int; 2015; 2015():478017. PubMed ID: 26351634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter validation of cancer gene panel-based next-generation sequencing for translational research and molecular diagnostics.
    Hirsch B; Endris V; Lassmann S; Weichert W; Pfarr N; Schirmacher P; Kovaleva V; Werner M; Bonzheim I; Fend F; Sperveslage J; Kaulich K; Zacher A; Reifenberger G; Köhrer K; Stepanow S; Lerke S; Mayr T; Aust DE; Baretton G; Weidner S; Jung A; Kirchner T; Hansmann ML; Burbat L; von der Wall E; Dietel M; Hummel M
    Virchows Arch; 2018 Apr; 472(4):557-565. PubMed ID: 29374318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integration of Liquid Biopsies into Clinical Laboratory Applications via NGS in Cancer Diagnostics.
    Sonmezler O; Boga I; Bisgin A
    Clin Lab; 2020 May; 66(5):. PubMed ID: 32390404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amplicon-Based NGS Panels for Actionable Cancer Target Identification in Follicular Cell-Derived Thyroid Neoplasia.
    Madsen MB; Kiss K; Cilius Nielsen F; Bennedbæk FN; Rossing M
    Front Endocrinol (Lausanne); 2020; 11():146. PubMed ID: 32265839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of multiple gene detection with a 22-gene panel in formalin-fixed paraffin-embedded specimens of 207 colorectal cancer patients.
    Gao XH; Yu GY; Hong YG; Lian W; Chouhan H; Xu Y; Liu LJ; Bai CG; Zhang W
    Int J Clin Oncol; 2019 Feb; 24(2):141-152. PubMed ID: 30612269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted Next Generation Sequencing as a Reliable Diagnostic Assay for the Detection of Somatic Mutations in Tumours Using Minimal DNA Amounts from Formalin Fixed Paraffin Embedded Material.
    de Leng WW; Gadellaa-van Hooijdonk CG; Barendregt-Smouter FA; Koudijs MJ; Nijman I; Hinrichs JW; Cuppen E; van Lieshout S; Loberg RD; de Jonge M; Voest EE; de Weger RA; Steeghs N; Langenberg MH; Sleijfer S; Willems SM; Lolkema MP
    PLoS One; 2016; 11(2):e0149405. PubMed ID: 26919633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical next-generation sequencing in patients with non-small cell lung cancer.
    Hagemann IS; Devarakonda S; Lockwood CM; Spencer DH; Guebert K; Bredemeyer AJ; Al-Kateb H; Nguyen TT; Duncavage EJ; Cottrell CE; Kulkarni S; Nagarajan R; Seibert K; Baggstrom M; Waqar SN; Pfeifer JD; Morgensztern D; Govindan R
    Cancer; 2015 Feb; 121(4):631-9. PubMed ID: 25345567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of the Oncomine
    Williams HL; Walsh K; Diamond A; Oniscu A; Deans ZC
    Virchows Arch; 2018 Oct; 473(4):489-503. PubMed ID: 30105577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and validation of the JAX Cancer Treatment Profile™ for detection of clinically actionable mutations in solid tumors.
    Ananda G; Mockus S; Lundquist M; Spotlow V; Simons A; Mitchell T; Stafford G; Philip V; Stearns T; Srivastava A; Barter M; Rowe L; Malcolm J; Bult C; Karuturi RK; Rasmussen K; Hinerfeld D
    Exp Mol Pathol; 2015 Feb; 98(1):106-12. PubMed ID: 25562415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implementation of next generation sequencing technology for somatic mutation detection in routine laboratory practice.
    Giardina T; Robinson C; Grieu-Iacopetta F; Millward M; Iacopetta B; Spagnolo D; Amanuel B
    Pathology; 2018 Jun; 50(4):389-401. PubMed ID: 29752127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients.
    Malapelle U; Mayo de-Las-Casas C; Rocco D; Garzon M; Pisapia P; Jordana-Ariza N; Russo M; Sgariglia R; De Luca C; Pepe F; Martinez-Bueno A; Morales-Espinosa D; González-Cao M; Karachaliou N; Viteri Ramirez S; Bellevicine C; Molina-Vila MA; Rosell R; Troncone G
    Br J Cancer; 2017 Mar; 116(6):802-810. PubMed ID: 28170370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive routine diagnostic screening to identify predictive mutations, gene amplifications, and microsatellite instability in FFPE tumor material.
    Steeghs EMP; Kroeze LI; Tops BBJ; van Kempen LC; Ter Elst A; Kastner-van Raaij AWM; Hendriks-Cornelissen SJB; Hermsen MJW; Jansen EAM; Nederlof PM; Schuuring E; Ligtenberg MJL; Eijkelenboom A
    BMC Cancer; 2020 Apr; 20(1):291. PubMed ID: 32264863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of cytocentrifugation supernatant fluid and formalin-fixed paraffin-embedded tissue for targeted next-generation sequencing.
    Janaki N; Harbhajanka A; Michael CW; Bomeisl P; Wasman J; Atchley M; Miskiewicz K; Alouani D; Sadri N
    Cancer Cytopathol; 2019 May; 127(5):297-305. PubMed ID: 30933438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Next-Generation Sequencing Analysis of Laser-Microdissected Formalin-Fixed and Paraffin-Embedded (FFPE) Tissue Specimens.
    Mägel L; Bartels S; Lehmann U
    Methods Mol Biol; 2018; 1723():111-118. PubMed ID: 29344856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of Factors Affecting the Success of Next-Generation Sequencing Testing in Solid Tumors.
    Goswami RS; Luthra R; Singh RR; Patel KP; Routbort MJ; Aldape KD; Yao H; Dang HD; Barkoh BA; Manekia J; Medeiros LJ; Roy-Chowdhuri S; Stewart J; Broaddus RR; Chen H
    Am J Clin Pathol; 2016 Feb; 145(2):222-37. PubMed ID: 27124905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of genomic alterations between tumor tissue and circulating tumor DNA by next-generation sequencing.
    Chang YS; Fang HY; Hung YC; Ke TW; Chang CM; Liu TY; Chen YC; Chao DS; Huang HY; Chang JG
    J Cancer Res Clin Oncol; 2018 Nov; 144(11):2167-2175. PubMed ID: 30203147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of an integrated clinical workflow for targeted next-generation sequencing of low-quality tumor DNA using a 51-gene enrichment panel.
    Choudhary A; Mambo E; Sanford T; Boedigheimer M; Twomey B; Califano J; Hadd A; Oliner KS; Beaudenon S; Latham GJ; Adai AT
    BMC Med Genomics; 2014 Nov; 7():62. PubMed ID: 25395014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.